Fedratinib

N/A

Report date: 2026/05/21 20:00:22
NME

Base Information

Drug NameFedratinib
Drug Alias Namefedratinib非卓替尼fedratinibum非屈替尼Inrebic +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase JAK2 inhibitorsTyrosine-protein kinase receptor FLT3 inhibitors
TargetsTyrosine-protein kinase JAK2Tyrosine-protein kinase receptor FLT3
Therapy Area/IndicationsSplenomegalyPrimary MyelofibrosisLeukemia, Neutrophilic, Chronic +[11] 
Global Approved IndicationsSplenomegalyPrimary Myelofibrosis
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2019/08/16
Country/TerritoryCzechiaBelgiumCanada +[30] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesSanofi
China Registration ClassN/A

Develop Information

Active CompaniesBristol Myers Squibb SrlcompanyImpact BiomedicinesRecordati Rare Diseases Inc +[7] 
Inactive CompaniesTargegen Inc
Active IndicationsSplenomegalyPrimary MyelofibrosisLeukemia, Neutrophilic, Chronic +[8] 
Inactive IndicationsRenal InsufficiencyHematologic NeoplasmsNeoplasms

Other Information

ATC CodeL01EJ02
Related LinksWikipediaDrugBankKEGG